Literature DB >> 2144745

CA-15.3, TPA and MCA as markers for breast cancer.

M Barak1, M Steiner, B Finkel, J Abrahamson, S Antal, N Gruener.   

Abstract

Serum concentrations of CA-15.3, tissue polypeptide antigen (TPA) and mucinous-like carcinoma-associated antigen (MCA) were measured in 327 women: 81 controls, 93 patients with benign breast disease, 46 patients recently diagnosed with breast cancer and 107 patients during breast cancer follow-up. CA-15.3 was elevated in 16% of the controls, in 29% of the patients with benign breast disease, in 65% of the breast cancer patients and in 74% of the follow-up patients. TPA was elevated in 4%, 11%, 36% and 75%, respectively. The corresponding figures for MCA were 10%, 8%, 30% and 64%. The highest sensitivity for cancer detection (74%) was obtained with a combination of CA-15.3 and TPA, while the specificity of this panel was 75%. The negative predictive value of these combined tests was 93%. MCA scored lower values, being only 30% sensitive. The CA-15.3/TPA panel may increase sensitivity compared with single marker tests and provide additional information for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144745     DOI: 10.1016/0277-5379(90)90081-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer.

Authors:  H Sonoo; J Kurebayashi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer.

Authors:  L C Pronk; G Stoter; W L van Putten; R de Wit
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

4.  Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.

Authors:  Luís C Fernandes; Su B Kim; Delcio Matos
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

5.  Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial.

Authors:  F Kovner; O Merimsky; M Hareuveni; N Wigler; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.

Authors:  E Vizcarra; A Lluch; R Cibrián; F Jarque; V Alberola; V Belloch; J García-Conde
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.

Authors:  Andrea Nicolini; Gianna Tartarelli; Angelo Carpi; Maria Rita Metelli; Paola Ferrari; Loretta Anselmi; Massimo Conte; Piero Berti; Paolo Miccoli
Journal:  BMC Cancer       Date:  2006-11-20       Impact factor: 4.430

8.  Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

Authors:  M Gion; M Plebani; R Mione; C Penzo; S Meo; A Burlina
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.